Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 673-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease

By Meerpohl H.G.   Sauerbrei W.   Kuhnle H.   Schumacher M.   Pfleiderer A.   German Ovarian Cancer Study Group GOCA  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 75-84

Elsevier

Access to resources Recommend Favorite

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

By  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1133-1133

Oxford University Press

Access to resources Recommend Favorite

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

By                  

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 773-781

Spandidos Publications

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite